Inaphaea Co-Marketing Agreement

Inaphaea Co

ValiRx is pleased to confirm the execution of a Memorandum of Understanding (the "Agreement") with emerging UK drug turnaround biotech Ignota Labs Limited ("Ignota Labs"), to collaborate on the exchange of data from Inaphaea's Biobank to generate insights, co-develop new assets, and explore joint business opportunities, including grant funding.

Ignota Labs will be entitled to analyse Inaphaea's Biobank data to develop or improve in-silico models which will support sourcing of new onocology assets with the intention of co-developing these assets using Inaphaea's tCRO® services and Ignota Labs' in-silico platform. The in-silico models will also be used for future services offered by Ignota Labs. Any revenues generated from the co-developed assets or servies will be shared between Ignota Labs and ValiRx, subject to a further revenue-sharing agreement to be agreed upon.

Mark Eccleston, CEO of ValiRx commented "ValiRx has utilised Ignota Labs' in-silico tox screening services for its in house evaluation projects and was impressed with the performance. This agreement leverages the data sets from Inaphaea's biobank to further develop Ignota Labs' in-silico capabilities which will benefit our early stage evaluation as well as providing an exciting new AI approach to asset discovery."

Sam Windsor CEO of Ignota Labs, commented "Ignota Labs has successfully developed a proprietary AI model, SAFEPATH, which applies a deep learning approach combined bioinformatics and cheminformatics datasets to solve drug safety issues. Inaphaea's data sets will be used to develop the next iteration of SAFEPATH and improve identification of the mechanisms of drug toxicity, predict effects on the human body, and balance that with therapeutic effectiveness. We can apply this approach to clinical candidates that have failed do to toxicity issues, stratify those which can be addressed and potentially identify new candidates, all based on in-silico modelling."